T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
NovaGold Resources
NG
$3.4B
| $315K | ﹤0.01% |
94,418
+14,601
| +18% | +$51.6K |
|
2477
Anavex Life Sciences
AVXL
$303M
| $314K | ﹤0.01% |
29,197
-33,912
| -54% | -$261K |
|
2478
Stoneridge
SRI
$201M
| $313K | ﹤0.01% |
49,790
-32,896
| -40% | -$253K |
|
2479
Hertz
HTZ
$838M
| $312K | ﹤0.01% |
85,029
+643
| +0.8% | +$2.32K |
|
2480
Surrozen
SRZN
$279M
| $312K | ﹤0.01% |
21,715
| – | – |
|
2481
Cadiz
CDZI
$295M
| $311K | ﹤0.01% |
59,636
+3,922
| +7% | +$14.1K |
|
2482
GoPro
GPRO
$117M
| $311K | ﹤0.01% |
284,835
+106,553
| +60% | +$135K |
|
|
ONTF
2483
DELISTED
ON24
ONTF
| $308K | ﹤0.01% |
47,632
+11,234
| +31% | +$72.1K |
|
2484
Cytek Biosciences
CTKB
$636M
| $307K | ﹤0.01% |
47,189
+7,686
| +19% | +$45.8K |
|
2485
Douglas Elliman
DOUG
$183M
| $307K | ﹤0.01% |
183,604
| – | – |
|
2486
Enliven Therapeutics
ELVN
$4.25B
| $307K | ﹤0.01% |
13,627
+1,980
| +17% | +$51.3K |
|
2487
Aclaris Therapeutics
ACRS
$863M
| $306K | ﹤0.01% |
123,100
-16,300
| -12% | -$40.6K |
|
2488
Daily Journal
DJCO
$828M
| $306K | ﹤0.01% |
537
-126
| -19% | -$67.4K |
|
|
MITT
2489
TPG Mortgage Investment Trust
MITT
$214M
| $305K | ﹤0.01% |
45,790
+2,047
| +5% | +$14.5K |
|
|
PVBC
2490
DELISTED
Provident Bancorp
PVBC
| $305K | ﹤0.01% |
26,730
+4,085
| +18% | +$45.2K |
|
|
RYZ
2491
Ryerson Holding Corp
RYZ
$1.5B
| $305K | ﹤0.01% |
16,455
+1,734
| +12% | +$38.9K |
|
|
NAGE
2492
Niagen Bioscience
NAGE
$241M
| $304K | ﹤0.01% |
57,304
+2,196
| +4% | +$12K |
|
2493
Hamilton Insurance Group
HG
$2.32B
| $302K | ﹤0.01% |
15,840
+2,726
| +21% | +$50.4K |
|
2494
Asure Software
ASUR
$251M
| $301K | ﹤0.01% |
31,899
+7,939
| +33% | +$73K |
|
2495
Central Pacific Financial
CPF
$1B
| $301K | ﹤0.01% |
10,331
+1,589
| +18% | +$47.3K |
|
2496
LivePerson
LPSN
$35.9M
| $301K | ﹤0.01% |
13,173
-1,364
| -9% | -$20.9K |
|
2497
Ezcorp Inc
EZPW
$1.76B
| $300K | ﹤0.01% |
24,495
-27,424
| -53% | -$326K |
|
2498
F&G Annuities & Life
FG
$3.59B
| $300K | ﹤0.01% |
7,236
+1,087
| +18% | +$47.9K |
|
|
GLDD
2499
DELISTED
Great Lakes Dredge & Dock
GLDD
| $299K | ﹤0.01% |
26,401
+5,155
| +24% | +$61.7K |
|
2500
Kiniksa Pharmaceuticals
KNSA
$6.07B
| $299K | ﹤0.01% |
15,111
+2,881
| +24% | +$65.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.